AcceGen Biotech
AcceGen Biotech is a US-based cell biology supplier, founded in 2017, cataloging 53,000+ primary cells, tumor lines, stem cells, and stable cell lines plus custom gene-editing services for academic and biopharmaceutical researchers across 40+ countries.
- Company typePrivate
- Founded2017
- HeadquartersFairfield, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AcceGen Biotech does
AcceGen Biotech is a US-based, privately-held cell biology supplier founded in 2017 and operating as a biological resource center for life-science researchers. The company catalogs 53,814+ products across primary cells (1,900+ SKUs spanning human and animal sources across 15 species and 9 organ systems), immortalized cell lines, tumor/cancer cell lines (1,249+), stem cells including iPSCs, ESCs, MSCs, and cancer stem cells (671+), and over 42,000 transfected stable cell lines (knockout, knockin, knockdown, overexpression, and reporter). Adjacent offerings include exosomes, microRNA Agomir/Antagomir products, nucleic acid kits, cell culture media, growth factors and cytokines, and custom research services spanning custom stable cell line development, iPSC gene editing, cell & gene therapy solutions, custom cell immortalization, lentivirus packaging, microRNA synthesis, and off-target analysis.
The underlying technology centers on cell isolation from fresh tissue, immortalization using EBV, HPV E6/E7, SV40 T antigens, hTERT and p53 delivered via lentivirus/retrovirus/adenovirus, lentivirus-based stable cell line construction, and iPSC gene editing. Quality assurance is implemented through STR genotyping authentication on every product and a panel of contamination tests covering viability, bacteria, fungi/yeast, mycoplasma, HIV, HBV, HCV, and syphilis.
AcceGen monetizes through per-item catalog sales (one-time license model) of cell products and reagents, supplemented by quote-based custom services (professional services model). Pricing is not publicly disclosed and operates on inquiry/quote mechanics. Go-to-market is a hybrid of direct e-commerce via accegen.com, a global distributor network with a dedicated Distributors page, and a Scientist.com marketplace listing, collectively reaching 500+ customers across 40+ countries. The company is bootstrapped (no funding rounds disclosed), operates with 11–50 employees, and reports 1,470+ scientific publications citing its products, indicating meaningful adoption across academic and biopharmaceutical research segments. Management team, ownership structure, and revenue figures are not publicly disclosed.
AcceGen Biotech firmographics
Firmographics- Name
- AcceGen Biotech
- Legal name
- AcceGen
- Website
- https://accegen.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AcceGen Biotech is a US-based cell biology supplier, founded in 2017, cataloging 53,000+ primary cells, tumor lines, stem cells, and stable cell lines plus custom gene-editing services for academic and biopharmaceutical researchers across 40+ countries.
- Ownership category
- akta.pro rank
AcceGen Biotech industry classification
Industry- Product category
- Cell Biology Products and Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where AcceGen Biotech is headquartered
LocationHeadquarters
- HQ city
- Fairfield
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AcceGen Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Cell Products Sales: Sale of biological products including primary cells, immortalized cell lines, tumor cell lines, stem cells, transfected stable cell lines, and related cell culture reagents. Products are sold directly through the company website with per-item pricing.
- Custom Cell Line Services: Custom stable cell line development, gene editing, CAR construction, and cell immortalization services. These are project-based services with custom pricing based on client requirements.
- MicroRNA Services: MicroRNA sponge services, microRNA Agomir/Antagomir synthesis, and lentivirus packaging services for RNA and gene modulation research.
- Cell Culture Reagents and Kits: Sale of cell culture media, kits, growth factors, cytokines, and other cell biology reagents. Complementary medium kits are included with cell product orders.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard cell products and services catalog with quote-based pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
AcceGen Biotech product offering
Product offeringCore offering
AcceGen Biotech manufactures and distributes authenticated cell biology products — including primary cells, immortalized cell lines, tumor cell lines, stem cells, transfected stable cell lines, microRNA reagents, exosomes, and cell culture media/reagents — for life science researchers. The company also provides custom research services such as custom stable cell line development, iPSC gene editing, cell immortalization, microRNA synthesis, lentivirus packaging, and off-target analysis. Offerings are sold individually or as project-based custom services to academic, biopharmaceutical, and oncology research customers in 40+ countries.
Product overview
AcceGen Biotech is a biotechnology company that provides a comprehensive portfolio of cell culture products and services for life science research. The company operates with a platform-plus-modules architecture, offering core cell products (Primary Cells, Immortalized Cell Lines, Tumor Cell Lines, Stem Cells, Transfected Stable Cell Lines, MicroRNA Agomir/Antagomir, Exosomes) complemented by add-on reagents (Cell Culture Media/Kits/Reagents, Nucleic Acid Kits) and custom research services (Custom Stable Cell Lines, iPSC Gene Editing, Cell & Gene Therapy Solutions, Custom Cell Immortalization, MicroRNA Services, Lentivirus Packaging, Off-Target Analysis). The company claims to provide over 53,000+ products including 4,011+ cell products and 48,877+ services, with offerings spanning human and animal primary cells, cancer cell lines, stem cells (including iPSCs), and genetically modified stable cell lines.
Differentiator
Problem solved
Functional benefit
Products and services
- Primary Cells
Quantifiable outcome
- Over 1,470 scientific publications citing AcceGen products, demonstrating validated research impact
- +2 more outcomes
Companies that use AcceGen Biotech
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles3 records
AcceGen Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AcceGen Biotech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Distributors (Global)coreAcceGen maintains a network of distributors globally as indicated by the dedicated Distributors page on their website. These distributors help extend the company's reach across 40+ countries where researchers access AcceGen products and services. Specific distributor names are not publicly listed on the website.
Scale indicators10 records
Recent moves6 records
Expansion highlights4 records
AcceGen Biotech competitors and assessment
Company assessmentDirect peers
- Creative Bioarray: US-based supplier of primary cells, cell lines, tissues, and custom cell services for research, directly overlapping with AcceGen's catalog and custom offering.
- ScienCell Research Laboratories: Specializes in human and animal primary cells, media, and reagents for research, closely matching AcceGen's core primary-cell product lines.
- Cell Biologics: Provides primary cells, immortalized cell lines, and media to life science researchers, competing directly with AcceGen's catalog.
- Applied Biological Materials (abm): Offers cell lines, lentiviral/viral packaging, gene editing, and custom stable cell line services, overlapping both AcceGen's products and engineering services.
- Cyagen Biosciences: Provides stem cells, custom cell line development, and gene editing services, mirroring AcceGen's stem cell and custom-service portfolio.
- GeneCopoeia: Supplies stable cell lines, viral vectors, and gene modulation reagents for research, overlapping AcceGen's stable cell line and lentivirus services.
Regional players
- PromoCell: Germany-based provider of human primary cells and culture media serving research labs, comparable in product focus but centered on European markets.
Broad incumbents
- ATCC: Established global biological materials repository supplying authenticated cell lines and microorganisms, an incumbent standard against which AcceGen's catalog competes.
- Lonza: Large life sciences company offering primary cells, media, and cell/gene therapy manufacturing as part of a broad portfolio overlapping AcceGen's niche.
- Merck (Sigma-Aldrich / ECACC): Global supplier of cell lines, culture reagents, and research materials whose life-science catalog broadly overlaps AcceGen's product range.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
AcceGen Biotech social profiles
Digital presenceAcceGen Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
AcceGen Biotech leadership team
Management profileNumber of profiles
AcceGen Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AcceGen Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AcceGen Biotech
What does AcceGen Biotech do?
AcceGen Biotech manufactures and distributes authenticated cell biology products — including primary cells, immortalized cell lines, tumor cell lines, stem cells, transfected stable cell lines, microRNA reagents, exosomes, and cell culture media/reagents — for life science researchers. The company also provides custom research services such as custom stable cell line development, iPSC gene editing, cell immortalization, microRNA synthesis, lentivirus packaging, and off-target analysis. Offerings are sold individually or as project-based custom services to academic, biopharmaceutical, and oncology research customers in 40+ countries.
Is AcceGen Biotech a public or private company?
AcceGen Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AcceGen Biotech founded?
AcceGen Biotech was founded in 2017. It employs 11 to 50 people.
Where is AcceGen Biotech based?
AcceGen Biotech is headquartered in Fairfield, United States, in the North America region.
How does AcceGen Biotech make money?
Four revenue lines are on record. Cell Products Sales are the primary driver. The others are custom Cell Line Services, microRNA Services and cell Culture Reagents and Kits.
Who are AcceGen Biotech's main competitors?
Direct peers on record are Creative Bioarray, ScienCell Research Laboratories, Cell Biologics, Applied Biological Materials (abm), Cyagen Biosciences and GeneCopoeia. PromoCell is listed as a regional player. Broad incumbents are ATCC, Lonza and Merck (Sigma-Aldrich / ECACC).
Does AcceGen Biotech have an API?
No public API is recorded for AcceGen Biotech.
What industry is AcceGen Biotech in?
AcceGen Biotech's product category is Cell Biology Products and Services. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.